Just because you don't pay as much as the sticker price is missing the point a bit, I'd say.
The Mylan version will also probably cost less than list for most people (though Mylan will get their money, just like the generic maker).
Also, you're correct that the price will come down over time. If the FDA had said, "this approval is part of a process that will eventually lower the cost within the next couple of years," then the article would make no sense. That's not what they said when this generic version was released.
The article is not claiming that generic drugs don't reduce prices. It is claiming that the narrative from the FDA, that this approval will reduce costs, is largely false.
However, it drops even more in 180 days.
In fact, several large retailers sell EpiPen for $150 when including a coupon, according to GoodRx.
As for the FDA narrative not being true, how do you know that? The article doesn't actually state the true cost of the Teva product anywhere, which was my original point.
Put another way, if I was working minimum wage without insurance and no other income (12% tax bracket), I'd need to work 13.6 hours to cover the drugs for that one condition, 34% of my take home (roughly, I didn't include state tax, social security, etc.). Where as one person I would have been above the poverty threshold of $12.14k in 2018, now I would effectively be below it.
This is why so many people who don't have steady jobs (e.g., the gig economy) have to choose between drugs and food.
In fact if you don't submit the claim for the medication to your insurance you may be able to reap that $100 of savings yourself in the form of a discount. Until very recently when the law changed to prevent it the contracts insurance companies had with pharmacies prevented your pharmacist from telling you that a drug could be obtained cheaper by not using your insurance.
I thought the patent-holder got exclusivity for 20 years, and then it was public domain. Why do we need a 2nd tier of exclusivity?
If all the generic manufacturers could rush in all at once, the price of the generic would falls to pretty much the cost of production quite quickly.
As a generic manufacturer, are you willing to spend $10M if you aren't sure you'll recoup it? Maybe.
But if you know for certain you'll be the only supplier for 6 months, then you have more certainty to make the investment.
I feel like people use that argument in other contexts but it would apply here too.
So in fact, this drug could be cheaper than the Mylan version, but it looks like they never dug in deeper to find out if it's true.
Second of all, the first generic approved gets 180 days of market exclusivity whereby the FDA will not approve any other generic versions. This is such that the generic manufacturer can recoup the investment prior to widespread competition that drives down prices.
For example, Lipitor went generic and the price dropped only ~10-20%. After the 180 days, multiple generic companies got approval and now the price is 80-90% lower.